Lakewood-Amedex Biotherapeutics

Company snapshot

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others.

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 18 US patent(s) indexed to this assignee profile.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Lakewood-Amedex Biotherapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Lakewood-Amedex Biotherapeutics.

1. Jun 5, 2026 Clinical update

   Antimicrobial agent — Phase 2

2. May 23, 2026 Clinical update

   5% Bisphosphocin Topical Gel — Phase 2

3. May 23, 2026 Clinical update

   5% Nu-3 gel — Phase 2

4. May 23, 2026 Clinical update

   Bisphosphocin Nu-3 — Phase 2

5. Dec 3, 2024 Patent grant

   Bisphosphocin gel formulations and uses thereof

View all clinical trial activity →

• What is Lakewood-Amedex Biotherapeutics?

  Lakewood-Amedex Biotherapeutics is a pharma organization headquartered in University Park, USA. It trades on NYSE under ticker LABT. Primary therapeutic focus areas include Chronic Diabetic Foot Ulcers, Diabetic Foot Infection, Diabetic Foot Ulcers (DFUs), Diabetic Foot Infection

• Is Lakewood-Amedex Biotherapeutics publicly traded?

  Yes. Lakewood-Amedex Biotherapeutics is listed with ticker LABT on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Lakewood-Amedex Biotherapeutics develop or market?

  We link 1 drug profile(s) where Lakewood-Amedex Biotherapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/lakewood-amedex-biotherapeutics#company-drugs.

• What are the latest developments for Lakewood-Amedex Biotherapeutics?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Lakewood-Amedex Biotherapeutics focus on?

  Lakewood-Amedex Biotherapeutics focuses on Chronic Diabetic Foot Ulcers, Diabetic Foot Infection, Diabetic Foot Ulcers (DFUs) based on our analysis of their pipeline programs and drug development activities.